Establishment Labs Holdings Inc.
Establishment Labs Holdings Inc.
Your view on ESTA
Overview
What the company does, where it operates, and who runs it.
About Establishment Labs Holdings Inc.
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Fillipo Peter Caldini
- Headquarters
- Building B15 and 25, Alajuela, CR
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Fillipo Peter Caldini
- Headquarters
- Building B15 and 25, Alajuela, CR
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name.
It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution.
The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Establishment Labs Holdings Inc., and the rating behind it. ESTA last traded at $70.94; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Establishment Labs Holdings Inc.. Starting points for Establishment Labs Holdings Inc.: EPS -$1.29, beta 1.05 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Establishment Labs Holdings Inc.. Establishment Labs Holdings Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Establishment Labs Holdings Inc.. Trailing twelve-month EPS for Establishment Labs Holdings Inc. stands at -$1.29. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Establishment Labs Holdings Inc.. Establishment Labs Holdings Inc. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Establishment Labs Holdings Inc. valued side by side against its closest peers. Establishment Labs Holdings Inc. is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Establishment Labs Holdings Inc., and how their positions are changing. At a $2.09B market value, institutional positions materially move Establishment Labs Holdings Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Establishment Labs Holdings Inc. executives and directors. Shares of Establishment Labs Holdings Inc. have traded between $26.56 and $69.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Establishment Labs Holdings Inc.. Establishment Labs Holdings Inc. is a $2.09B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Establishment Labs Holdings Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Establishment Labs Holdings Inc.. Coverage tracks Establishment Labs Holdings Inc. within Medical - Devices (Healthcare). Press releases and market coverage, newest first.